Familial defective apolipoprotein B-100 (FDB) and familial hypercholesterolemia (FH) are the common causes of monogenic primary hypercholesterolemia. An individual of mixed English and Afrikaner descent with both FDB and the FH Afrikaner-1 low-density lipoprotein receptor mutation was identified in our laboratory. Subsequent analysis of her extended family revealed the presence of heterozygotes for either FH Afrikaner-1, FH Afrikaner-2, or FDB as well as five additional double heterozygotes for FH Afrikaner-1 and FDB and one "complex" heterozygote with all three mutations. The hypercholesterolemic and clinical features of the pure FDB subjects were similar to those of the pure FH heterozygotes. The Afrikaner population in South Africa has a particularly high incidence (=1/70) of monogenic hypercholesterolemia 7 that is largely but not completely accounted for by three founder LDL receptor mutations, the so-called FH Afrikaner-1, -2, and -3 mutations. In contrast, the incidence of FDB in this population seems to be lower than 1/500 (D.C. Rubinsztein, MD, et al, unpublished results). In this study we have identified a large family of mixed English and Afrikaner descent that is characterized by the presence of both the FDB as well as FH Afrikaner-1 and Afrikaner-2 LDL receptor mutations.
F amilial defective apolipoprotein (apo) B-100
(FDB) (an A r g^ to Gin substitution) and familial hypercholesterolemia (FH) (low-density lipoprotein [LDL] receptor mutations) are the common causes of monogenic primary hypercholesterolemia. Both autosomal dominant disorders have a prevalence of about 1/500 in North American and European Caucasian populations. 12 Unlike FH, which is caused by many different LDL receptor mutations, 1 FDB seems to have resulted from a single founder-type mutation that occurred only once on an ancestral chromosome. 3 Although initial reports suggested that FDB is a milder disease than FH, 2 subsequent studies have indicated that the clinical and biochemical sequelae of these two genetic disorders are often very similar. 4 - 5 In addition, patients with FDB apparently respond to the same extent as those with FH to lipid-lowering drugs that upregulate LDL receptors. 6 The Afrikaner population in South Africa has a particularly high incidence (=1/70) of monogenic hypercholesterolemia 7 that is largely but not completely accounted for by three founder LDL receptor mutations, the so-called FH Afrikaner-1, -2, and -3 mutations. 810 In contrast, the incidence of FDB in this population seems to be lower than 1/500 (D.C. Rubinsztein, MD, et al, unpublished results). In this study we have identified a large family of mixed English and Afrikaner descent that is characterized by the presence of both the FDB as well as FH Afrikaner-1 and Afrikaner-2 LDL receptor mutations.
In addition to heterozygotes for either the FH Afrikaner-1, FH Afrikaner-2, or FDB mutations, six individuals who are double heterozygotes for the FH Afrikaner-1 and FDB mutations were identified, as well as one "complex" heterozygote who possessed all three mutations. This large pedigree allowed the clinical comparison of these various genotypes and their combinations within a single kindred.
Methods

Patients
Patients attended the Lipid Clinic at the Johannesburg General Hospital. Blood was obtained with informed consent and appropriate institutional approval.
DNA Isolation
DNA isolation from blood was carried out as described by Talmud et al.
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T from UK exist in at least two different functional subpopulations: one that binds LDL normally and the other that has defective LDL binding. 13 FH Afrikaner-2 (VaLwe^Met) is also slowly processed, and very low numbers of FH Afrikaner-2 receptors are present on the cell surface, as these mature receptors are abnormally rapidly degraded.
12 FH Afrikaner-3 (Asp 1M -»Asn) produces slowly processed receptors that are prone to being degraded in their immature form, and those receptors that do reach the cell surface have impaired LDL binding at 3TC (F.G. van Roggen, MD, et al, unpublished results).
The FH Afrikaner-1 and -3 mutations were detected by a polymerase chain reaction (PCR)-based assay in which part of exon 4 of the LDL receptor was amplified and subsequently digested with either Dde I (FH Afrikaner-1) or Mbo II (FH Afrikaner-3), as described previously. 8 The FH Afrikaner-2 mutation was detected with an amplification refractory PCR assay devised by M. Kotze, PhD, and E. Langenhoven, PhD (unpublished results). This assay is based on a 3' match/mismatch of oligonucleotides at the site of the point mutation to yield or not yield a PCR product, respectively.
The FDB mutation was detected by the method described by Hansen et al. 14 In this method, a PCRamplified DNA fragment is digested with Msp I to distinguish the normal and mutant sequences. FDB, familial defective apolipoprotein B-100; FH, familial hypercholesterolemia; CHD, coronary heart disease; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; apo, apolipoprotein; Y, yes; N, no; AESM, aortic ejection systolic murmur.
*tt5|1#**tttt § §111##*Values in the designated groups were compared by unpaired two-tailed t tests; P<.005 in all cases. b TC, TG, HDL cholesterol, and LDL cholesterol concentrations are expressed in millimoles per liter. All patients with gene defects were sampled while they were off cholesterol-reducing medication.
c Apo E genotypes were determined as described by Hixson and Vernier. Restriction enzyme isotyping of apo E polymorphisms was carried out by PCR amplification and digestion with Hha I as described by Hixson and Vernier. 15 
Lipoprotein Analysis
Total cholesterol, triglycerides, and high-density lipoprotein cholesterol were quantified by enzymatic methods using automated techniques. 16 LDL cholesterol levels were calculated using the Friedewald formula.
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Results
The proband II.3 in the W. family (Fig 1) was initially diagnosed as an FH heterozygote who had a high total cholesterol level. DNA analysis, however, revealed that the patient is a double heterozygote who has both the FH Afrikaner-1 and FDB mutations. Members from her very large family were screened for the FH Afrikaner-1, FH Afrikaner-2, and FH Afrikaner-3 mutations as well as for FDB (Table) . The availability of a number of individuals with various combinations of FH and FDB allowed us to examine and compare the clinical and biochemical features of these genetic disorders (Table) . Noticeably, none of the FH heterozygotes, FDB heterozygotes, or even the double heterozygotes showed evidence of coronary artery disease, as assessed on clinical grounds. However, given the small numbers of patients in each group and their relatively young ages, these findings are not discordant with the clinical features reported for FH or FDB. 18 Clearly, there is a strong family history of coronary artery disease, with several family members having died of myocardial infarction in their third to fifth decades. None of the heterozygotes for either FH Afrikaner-1, FH Afrikaner-2, or FDB had xanthomata or Achilles tendon thickening (Table) , whereas three of the six FH Afrikaner-1/FDB double heterozygotes had these stigmata. This might be significant, as these three double heterozygotes were of similar ages to some of the patients with just one mutation.
In the heterozygote groups, total cholesterol levels were similar in the FH Afrikaner-1 (8.5 ±1.2 mmol/L) and FDB (7.5 ±1.8 mmol/L) heterozygotes and were significantly higher than those of the normal subjects in the same family (5.3±1.2 mmol/L). The LDL cholesterol levels in the FH Afrikaner-l (6.7±1.0 mmol/L), FDB (5.6±1.4 mmol/L), and normal (3.5±1.0 mmol/L) subjects followed the same trend as the total cholesterol levels. Only one FDB heterozygote, 111.21, had a relatively normal lipid profile with total and LDL cholesterol levels of 5.0 and 3.6 mmol/L, respectively, at age 23. The reason(s) for this is not clear at this stage. Similarly, the reason(s) for the frank hypercholesterolemia of subject II.4, who has no known mutations, is also unknown. He had no obvious secondary causes for hypercholesterolemia.
The FH Afrikaner-1 and FDB double heterozygotes were compared with heterozygotes having only one mutation and with FH Afrikaner-1 homozygotes (Table). The total and LDL cholesterol levels of the FH Afrikaner-1/FDB double heterozygotes, 13.2±2.0 mmol/L and 11.5±2.8 mmol/L, respectively, were markedly higher than those of individuals who had just one of the mutations and were lower than in FH Afrikaner-1 homozygotes. The extremely severe hypercholesterol-emia of the one FH Afrikaner-2 heterozygote, H.l, is unexplained. This postmenopausal woman was on no hormone replacement therapy.
A graphic presentation of LDL cholesterol values as a function of age clearly illustrates the differences between the various groups (Fig 2) . The FDB/FH Afrikaner-1 double heterozygotes clearly had the highest LDL cholesterol values at all ages, whereas the normal group had the lowest. The two single-heterozygote groups were indistinguishable from each other and had cholesterol values between those of normal subjects and double heterozygotes. The effect of age on the LDL cholesterol values was clearly apparent and was significant in the case of normal subjects and double heterozygotes.
The clinical features of III.9, the "complex" heterozygote with FH-Afrikaner 1, FH Afrikaner-2, and FDB, seem to be similar to those of an FH homozygote. Before his partial ileal bypass surgery in 1981 (at age 14), he had LDL cholesterol levels of more than 20 mmol/L (age 12), a corneal arcus, and extensive planar and tendon xanthomata. His total cholesterol levels have dropped to 13.7 mmol/L (age 24) and his xanthomata have largely regressed since the partial ileal bypass surgery. He was not on any lipid-lowering medication for at least a year before this examination. However, although he is asymptomatic at present, he has a 2/6 aortic ejection systolic murmur and carotid bruits that are evidence of premature atherosclerosis. The discovery of the W. family, which includes FH Afrikaner-1, FH Afrikaner-2, and FDB heterozygotes, double heterozygotes for FH Afrikaner-1 and FDB, and an individual with all three of the aforementioned mutations, allowed comparison of the ligand and receptor diseases not only in isolation in the same kindred but also in combination. To our knowledge only one case of a double heterozygote of an LDL receptor mutation and FDB has been reported. 20 In that case the LDL receptor deficiency was diagnosed by determining 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in skin fibroblasts, and the genetic nature of the LDL receptor mutation was not revealed. The conclusion was that the double heterozygote was clinically very similar to patients heterozygous for either defect. The W. family allowed the comparison of six such double heterozygotes with a similar number of FH Afrikaner-l and FDB heterozygotes. The advantage of this is that many of the environmental and genetic factors that affect lipoprotein metabolism are likely to be shared in these patients and the groups they are being compared with.
Discussion
The clinical features of the FH Afrikaner-1 and FDB heterozygotes were very similar and were clearly less severe than those of the double heterozygotes of FH Afrikaner-1 and FDB, both in terms of lipid levels and clinical features. The typical double heterozygote seems to have total cholesterol levels (13.17±2.86 mmol/L) that fall between the average levels found in FH heterozygotes (8.96±1.81 mmol/L) and those in homozygotes (18.7±3.4 mmol/L) (Table) . The ranges of total cholesterol concentrations quoted by Goldstein and Brown 1 for heterozygous and homozygous FH are 6.5 to 12.9 mmol/L and 15.5 to 25.8 mmol/L, respectively. Intuitively, one would expect the double heterozygotes to be more severely affected than FDB heterozygotes, since there are not the normal number of receptors available to clear the apo B-100-LDL particles. Similarly, they should be worse off than FH heterozygotes, since fewer than 50% of the LDL particles are competent ligands 2 for the already-reduced LDL receptor complement. However, one would not expect these double heterozygotes to be as severely affected as FH homozygotes, since a significant proportion of both LDL particles and LDL receptors are normal.
The clinical presentation of the "complex" heterozygote who had both FH Afrikaner-1 and -2 mutations and FDB was similar to that of a normal homozygote with two mutant LDL receptor alleles. 1 It is not possible at present to say whether this subject is more severely affected with the apo B mutation than he might have been without it. The FH Afrikaner-1 mutation does allow the expression of a significant number of functional receptors, as studied in cultured cells, whereas the FH Afrikaner-2 mutation is practically a null mutation because of the very short half-life of the mutant protein. 12 Thus, a heteroallelic compound heterozygote for these two mutations would be expected to have some residual LDL receptor activity. 21 In such a case, the greater the residual LDL receptor activity, the greater will be the liability of the additional FDB mutation. Nevertheless, the clinical sequelae would probably not be more severe than those in a patient with two null LDL receptor alleles, as it is unlikely that any significant normal apo B-100-mediated LDL clearance occurs in the absence of LDL receptors.
The presence of the combination of both apo B and LDL receptor gene defects in individuals in this family underlines the importance of testing for both classes of defects in the appropriate populations and patient groups at risk. Populations that have a particularly high frequency of either FDB or LDL receptor mutations are more likely to contain individuals with both types of defect. This scenario should be considered in "FH heterozygotes" with higher-than-expected lipid levels that do not drop as close to normal as one would expect on simvastatin or similar therapy. The identification of one of these two causes of monogenic hypercholesterolemia in such cases should not be considered completely diagnostic unless the other class of defect has been ruled out.
